Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (49)	4/20/2001 9:17:13 PM
From: Scott H. Davis	of 544

RE: MM's target - did he perhaps include a timeframe? I actually can see VICL at 100 - 3-4 years out if 3 or these 5 events come to fruition 1. Approval of Allovectin-7 - PIII going well - would be 1st gene based therapy approved by FDA & unpartnered revenue. 2. Successful HIV vaccine by MRK using VICL technology 3. Successfull Malaria vaccine (currently in PII) 4. Successful FLU vaccine using their technology (as it contains a common Flu DNA fragment, would not have to be re-done each year, and without risk of causing flu) 5. A couple biggies licensing their naked DNA technology. Lots of cash to continue development, accompanied by a slow burn rate, and pretty good management allocation of recources to programs. one thing to keep in mind is that this was the 1st bad news tem in 4 years. Not too many biotechs with as many things going on as they do can say that. IMSCO Scott

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next